In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts. - Randall J; Evans K; Watts B; Kosasih HJ; Smith CM; Earley EJ; Erickson SW; Jocoy EL; Bult CJ; Teicher BA; de Bock CE; Smith MA; et al. (Experimental hematology, 2024)